Black Diamond Therapeutics reported total assets of $115.6 million as of September 30, 2026, a decrease from $143.0 million at year-end 2025. The company is focused on advancing its lead candidate silevertinib toward Phase 3 trials and managing its partnership with Servier Pharmaceuticals for BDTX-4933.
Black Diamond Therapeutics reported Q3 2026 financial results and updated Phase 2 data for silevertinib in frontline NSCLC, showing an 86% CNS-ORR in patients with brain metastases. The company received FDA feedback supporting a pivotal Phase 3 trial design with potential for accelerated approval. Current cash reserves of $102.0 million are expected to fund operations into the second half of 2028.
Term
Q3 2026
“Our recent end of Phase 2 meeting with the FDA was highly collaborative, and we believe the feedback we received supports a clear path to potential accelerated and full approval for silevertinib in frontline NSCLC patients with EGFR non-classical mutations. This trial design offers a differentiated path to potential accelerated approval in EGFR-NCM patients, who represent about 25% of the frontline EGFR mutant patient population.”
Mark Velleca, M.D., Ph.D., President and Chief Executive Officer
“We believe that silevertinib’s ability to significantly delay CNS progression is the key driver of the durable clinical benefit we are seeing in patients both with and without baseline brain metastases and is the foundation of the pivotal program design in 1L NSCLC.”
Sergey Yurasov, M.D., Ph.D., Chief Medical Officer